News headlines about Arcadia Biosciences (NASDAQ:RKDA) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arcadia Biosciences earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the basic materials company an impact score of 45.2077264915636 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, Piper Jaffray Companies set a $1.00 price objective on Arcadia Biosciences and gave the stock a “hold” rating in a report on Saturday, July 22nd.
Arcadia Biosciences (NASDAQ RKDA) traded down 11.2336% on Tuesday, hitting $0.3461. The stock had a trading volume of 142,608 shares. Arcadia Biosciences has a 1-year low of $0.30 and a 1-year high of $1.95. The firm’s market capitalization is $14.77 million. The stock’s 50-day moving average is $0.42 and its 200 day moving average is $0.56.
Arcadia Biosciences (NASDAQ:RKDA) last issued its earnings results on Thursday, August 10th. The basic materials company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Arcadia Biosciences had a negative net margin of 499.59% and a negative return on equity of 87.43%. The company had revenue of $0.99 million for the quarter. On average, equities research analysts predict that Arcadia Biosciences will post ($0.36) earnings per share for the current fiscal year.
About Arcadia Biosciences
Arcadia Biosciences, Inc is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market.
Receive News & Ratings for Arcadia Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences Inc. and related companies with our FREE daily email newsletter.